Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth

Publisher Name :
Date: 31-Oct-2013
No. of pages: 112

GBI Research has released the pharmaceutical report “Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth”. The current market for breast cancer consists of five monoclonal Antibodies (mAbs), three of which are targeted at the Human Epidermal growth factor Receptor 2 (HER-2) protein. Four are aimed at improving overall survival in the metastatic setting, and two of these have also received further approvals in the early setting in order to improve long-term remission rates. The market is currently led by the HER-2 inhibitor Herceptin, which achieved global sales amounting to $6.2 billion in 2012. Over the forecast period from 2012 to 2019, the two novel HER-2 inhibitors, Kadcyla and Perjeta, are expected to achieve strong market penetration due to their appreciable incremental efficacy benefits. Additionally, the market conditions are currently favorable towards mAbs, with a low rate of price depreciation following patent expiry and a high rate of inflation for specialty pharmaceuticals in the US. As a result of this, and despite the empty Phase III pipeline, GBI Research believes that the global market across the leading eight countries have the potential to grow to a value of $10.6 billion by 2019.

Scope


  • An introduction to the treatments available for breast cancer, treatment algorithms and the contexts in which mAbs are clinically relevant to this type of cancer.

  • In-depth analysis of the five mAbs approved for breast cancer, with analysis of their safety, efficacy, treatment patterns and strengths and weaknesses. This includes a heat map comparing the drugs in terms of clinical trial results.

  • A comprehensive review of the pipeline for breast cancer therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline for mAbs is analyzed on the basis of phase distribution, program type and molecular target, as is the entire pipeline for all molecule types.

  • Detailed analysis of pipeline drug clinical trials by trial size, trial duration and program failure rate for each molecule type and mechanism of action. Additionally, a detailed analysis of clinical trial endpoints is provided, detailing their importance in this disease area and their commercial relevance to currently marketed products.

  • Multi-scenario forecast data for the market is provided to 2019, which takes into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets including the US, Japan, Germany, the UK, France, Italy and Spain.

  • Discussion of the drivers and barriers for market growth

  • Complete analysis of licensing and co-development deals in this market, by year, value, molecule type, Phase and mechanism of action. Additionally, the international network of licensing deals in breast cancer is mapped out by geography.


Reasons to Buy

  • Understand the different indications for breast cancer, from early-stage to the metastatic disease

  • Grasp the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent, and the context of mAbs in the pipeline

  • Pinpoint the trends in clinical trial duration and size amongst clinical Phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for breast cancer therapeutics. Determine the risk associated with the development of mAbs compared to other molecule types.

  • Observe the shift in clinical trial endpoints by clinical Phase, and use this data to potentially influence any future developmental programs. Understand the importance of selecting the correct endpoints in the study of drugs for this disease.

  • Assess the potential clinical and commercial impact of recently-approved molecules on the breast cancer market and determine the potential revenues associated with the launch of a novel product, in addition to the level of competitiveness in the market.

Monoclonal Antibodies Market in Breast Cancer to 2019 - Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth

Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Monoclonal Antibodies Market in Breast Cancer to 2019 – Introduction 9
2.1 Symptoms 9
2.2 Etiology 9
2.3 Epidemiology 10
2.4 Pathophysiology 10
2.5 Diagnosis 11
2.6 Prognosis and Disease Staging 11
2.6.1 Classification 13
2.7 Treatment Options 13
2.7.1 Surgery and Radiation Therapy 13
2.7.2 Chemotherapy 14
2.7.3 Hormonal Therapies 15
2.7.4 Targeted Therapies 15
2.7.5 Resistance to Pharmacological Therapies 16
2.7.6 Treatment Guidelines 17
2.7.7 Measuring the Effectiveness of Treatment 19

3 Marketed Products 20
3.1 Herceptin (Trastuzumab) – Hoffmann La Roche 20
3.2 Avastin (Bevacizumab) – Hoffmann La Roche 23
3.3 Kadcyla (Trastuzumab Emtansine) – Hoffmann La Roche 25
3.4 Perjeta (Pertuzumab) – Hoffmann La Roche 26
3.5 Xgeva (denosumab) – Amgen 27
3.6 Heat Map for Marketed Products 28
3.7 Conclusion 30

4 Pipeline for Breast Cancer Monoclonal Antibody Therapeutics 31
4.1 Overall Pipeline 32
4.2 Mechanisms of Action 34
4.3 Clinical Trials 37
4.3.1 Attrition Rate 37
4.3.2 Clinical Trial Size 38
4.3.3 Duration 40
4.3.4 Clinical Trial End-points 42
4.4 Promising Drug Candidates in the Pipeline 44
4.4.1 CDX-011 (glembatumumab vedotin) – Celldex Therapeutics 44
4.4.2 Metmab (onartuzumab) – Hoffman La Roche 44
4.4.3 Hu3S193 – Recepta Biopharma 44
4.4.4 MM-121 – Merrimack Pharmaceuticals 45
4.4.5 IMC-18F1 (Icrucumab) – Eli Lilly 45
4.4.6 Rexomun (Ertumaxomab) – Fresenius Biotech 45
4.4.7 Medi-573 (Dusigitumab) – Medimmune 45
4.4.8 MK-0646 (Dalotuzumab) – Merck and Co 46
4.4.9 LY3012217 (Cixutumumab) - Eli Lilly 46
4.5 Conclusion 46

5 Market Forecast to 2019 48
5.1 Global 48
5.1.1 Treatment Usage Patterns 48
5.1.2 Market Size 49
5.2 US 50
5.2.1 Treatment Usage Patterns 50
5.2.2 Market Size 51
5.3 Canada 52
5.3.1 Treatment Usage Patterns 52
5.3.2 Market Size 53
5.4 Europe 54
5.4.1 Treatment Usage Patterns 54
5.4.2 Annual Cost of Therapy 55
5.4.3 Market Size 56
5.5 Japan 57
5.5.1 Treatment Usage Patterns 57
5.5.2 Market Size 58
5.6 Drivers and Barriers 59
5.6.1 Drivers 59
5.6.2 Barriers 59

6 Deals and Strategic Consolidations 60
6.1 R&D Licensing Agreements 60
6.1.1 Key Licensing Deals 63
6.2 Co-development Agreements 65
6.2.1 Key Deals 65

7 Appendix 68
7.1 References 68
7.2 References for Heat Map 73
7.3 All Pipeline Products, by Phase 74
7.3.1 Discovery 74
7.3.2 Preclinical 77
7.3.3 IND/CTA Filed and Phase I 89
7.3.4 Phase II 95
7.3.5 Phase III and Pre-Registration 102
7.4 Market Definitions 104
7.5 Abbreviations 105
7.6 Tabular Forecast Data 106
7.6.1 Global 106
7.6.2 US 106
7.6.3 Canada 106
7.6.4 UK 107
7.6.5 France 107
7.6.6 Germany 107
7.6.7 Italy 107
7.6.8 Spain 108
7.6.9 Japan 108
7.7 Research Methodology 109
7.7.1 Coverage 109
7.7.2 Secondary Research 109
7.8 Therapeutic Landscape 110
7.9 Epidemiology-Based Forecasting 110
7.10 Market Size by Geography 111
7.11 Geographical Landscape 112
7.12 Pipeline Analysis 112
7.13 Competitive Landscape 112
7.13.1 Expert Panel Validation 112
7.14 Contact Us 112
7.15 Disclaimer 112

List of Tables

Table 1: Market for mAbs in Breast Cancer, Global, TNM Staging, 2010–2013 11
Table 2: Market for mAbs in Breast Cancer, US, Disease Stage at Diagnosis and Five-year Relative Survival (%), 2013 12
Table 3: Market for mAbs in Breast Cancer, References for Heat Map (Figure 6) 73
Table 4: Breast Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2013 74
Table 5: Breast Cancer Therapeutics, Global, All Pipeline Products (Preclinical), 2013 77
Table 6: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase I and IND/CTA filed), 2013 89
Table 7: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2013 95
Table 8: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase III and Pre-Registration), 2013 102
Table 9: Market for mAbs in Breast Cancer, Global, Forecast Data, 2012–2019 106
Table 10: Market for mAbs in Breast Cancer, US, Forecast Data, 2012–2019 106
Table 11: Market for mAbs in Breast Cancer, Canada, Forecast Data, 2012–2019 106
Table 12: Market for mAbs in Breast Cancer, UK, Forecast Data, 2012–2019 107
Table 13: Market for mAbs in Breast Cancer, France, Forecast Data, 2012–2019 107
Table 14: Market for mAbs in Breast Cancer, Germany, Forecast Data, 2012–2019 107
Table 15: Market for mAbs in Breast Cancer, Italy, Forecast Data, 2012–2019 107
Table 16: Market for mAbs in Breast Cancer, Spain, Forecast Data, 2012–2019 108
Table 17: Market for mAbs in Breast Cancer, Japan, Forecast Data, 2012–2019 108

List of Figures

Figure 1 Market for mAbs in Breast Cancer, Global, Treatment Algorithm for Cancer Diagnosed at Stages I to III 17
Figure 2: Market for mAbs in Breast Cancer, Global, Treatment Algorithm for Cancer Diagnosed at Stage IV 18
Figure 3: Market for mAbs in Breast Cancer, Global, Sales of Herceptin ($bn), 1999–2012 21
Figure 4: Market for mAbs in Breast Cancer, Global, Sales of Avastin ($bn), 2004–2012 24
Figure 5: Market for mAbs in Breast Cancer, Global, Aggregate Sales of Xgeva and Prolia ($m), 2010–2012 27
Figure 6: Market for mAbs in Breast Cancer, Global, Heat Map (Marketed Products) 29
Figure 7: Market for mAbs in Breast Cancer, Global, Pipeline by Stage of Development, 2013 32
Figure 8: Market for mAbs in Breast Cancer, Global, mAbs by Mechanism of Action, 2013 34
Figure 9: Market for mAbs in Breast Cancer, Global, mAbs by Mechanism of Action (Growth Factor Inhibitors), 2013 35
Figure 10: Market for mAbs in Breast Cancer, Global, mAbs by Molecular Target (Targeted Cytotoxic), 2013 36
Figure 11: Market for mAbs in Breast Cancer, Global, Pipeline by Stage of Development, 2013 37
Figure 12: Market for mAbs in Breast Cancer, Global, Pipeline by Stage of Development, 2013 38
Figure 13: Market for mAbs in Breast Cancer, Global, Clinical Trial Size, 2013 39
Figure 14: Market for mAbs in Breast Cancer, Global, Clinical Trial Duration, 2006–2013 40
Figure 15: Market for mAbs in Breast Cancer, Global, Clinical Trial Durations, 2006–2013 41
Figure 16: Market for mAbs in Breast Cancer, Global, Clinical Trial Endpoints for Phases II and III, 2006–2012 42
Figure 17: Market for mAbs in Breast Cancer, Global, Clinical Trial Endpoints for Phases II and III per Product, 2006–2012 43
Figure 18: Market for mAbs in Breast Cancer, Global, Treatment Usage Patterns, 2012–2019 48
Figure 19: Market for mAbs in Breast Cancer, Global, Market Size ($bn), 2012–2019 49
Figure 20: Market for mAbs in Breast Cancer, US, Treatment Patterns, 2012–2019 50
Figure 21: Market for mAbs in Breast Cancer, US, Market Size ($bn), 2012–2019 51
Figure 22: Market for mAbs in Breast Cancer, Canada, Treatment Usage Patterns, 2012–2019 52
Figure 23: Market for mAbs in Breast Cancer, Canada, Market Size ($m), 2012–2019 53
Figure 24: Market for mAbs in Breast Cancer, Top Five European Markets, Treatment Usage Patterns, 2012–2019 54
Figure 25: Market for mAbs in Breast Cancer, Top Five European Markets, Annual Cost of Therapy ($), 2012–2019 55
Figure 26: Market for mAbs in Breast Cancer, Top Five European Markets, Market Size ($m), 2012–2019 56
Figure 27: Market for mAbs in Breast Cancer, Japan, Treatment Usage Patterns, 2012–2019 57
Figure 28: Market for mAbs in Breast Cancer, Japan, Market Size ($m), 2012–2019 58
Figure 29: Market for mAbs in Breast Cancer, Global, Licensing Deals (All Molecule Types), 2006–2012 (A) 60
Figure 30: Market for mAbs in Breast Cancer, Global, Licensing Deals (All Molecule Types), 2006–2012 (B) 61
Figure 31: Market for mAbs in Breast Cancer, Global, Licensing Deals (All Molecule Types), 2006–2012 (C) 62
Figure 32: Market for mAbs in Breast Cancer, Global, Co-development Deals (All Molecule Types) by Partner Country, 2006–2012 65
Figure 33: Market for mAbs in Breast Cancer, Global, Co-development Deals by Molecule Type, 2006–2012 66
Figure 34: GBI Research Market Forecasting Model 111

  • Ferulic Acid Market 2019 Forecasts Company Profile, Product Specifications & Capacity
    ‘Market Research Report on Global and Chinese Ferulic Acid (CAS 1135-24-6) Industry, 2009-2019’ is a top-notch market study report that delivers thorough understanding of market landscape and key-aspects of the ferulic acid industry. The research report systematically incorporates numerous elaborative sections and segments that aim at delivering most-accurate business statistics and premium industry insight to [...]
  • Overview of Global and Chinese 3D Printing Market 2015-2020
    ‘2015 3D Printing Industry Report -Global and Chinese Market’ is a comprehensive research report that describes the scope of the Global and Chinese 3D printing industry, analyzing the end-users behavior and the latest industry trends. Also, the report evaluates the growth prospects and the up-coming opportunities in the industry over the forecast period of 2015-2020. [...]
  • Schottky Diode Industry Research – 2015 Global and Chinese Market Overview
    ‘2015 Schottky Diode Industry Report – Global and Chinese Market Scenario’ is a top-notch research report, delivering premium industry insights and explanations of complex business scenarios. The report systematically articulates various growth prospects and current market challenges being faced by the existing industry players. The research report also drafts a meticulous business forecast that provides [...]
  • Codeine (CAS 76-57-3) Industry Research Report – 2009-2019 Market Forecast
    ‘Global and Chinese Codeine (CAS 76-57-3) Industry, 2009-2019 Market Research Report’, a systematically structured research report, that aims to deliver a detailed understanding of vivid market scenarios prevalent in the Codeine (CAS 76-57-3) industry to the user.  The report articulates various sections that thoroughly describe all key-aspects of the Codeine (CAS 76-57-3) industry. The report [...]
  • Global and Chinese Mainframe Banking Industry 2015 Outlook
    2015 Banks Mainframe Industry Report -Global and Chinese Market is a detailed market research report, delivering premium industry insights and analyzing the growth prospects of the industry over the forecast period of 2015-2020. The systematically structured sections of the research report, aims at conveying a strong business understanding to the user, enhancing the decision making [...]
    • The Oil Drilling Rig Industry
    • The Oil Drilling Rig Industry is characterized with a few typical work specific to this industry only. The work begins with the search for new oil basins or construction of wells. During this time the services of drilling contractors and se…

    • HER2-Negative Breast Cancer’s Therapeutic Market
    • HER2-Negative Breast Cancer is the most common form of cancer occurring in women. The long term survival of patients diagnosed with HER2-Negative Breast Cancer depends solely on its early detection as till now there is no medicine that can …

    • The Market of Plate Heat Exchanger
    • Plate heat exchanger is not only very useful but its also easy to maintain, its compact design makes it more efficient, the product is highly cost-efficient and also the materials of this product are easily available. There are some limitat…

    • The Industry of Binding Machines
    • Binding of books and papers is one of the most important aspect of buying and selling books and thus the demand of binding machines. There are different kinds of binding machines available in the market. The binding type determines the bind…

    • The Boom In Women Infertility Market
    • Infertility is an abnormality in the regular functioning of the human reproductive system. Anyone of male or female might be suffering from this issue. Infertility in woman is caused by either a genetical factor or factors such as aging or …

  • Abraxane (Breast cancer) - Analysis and Forecasts to 2020
    Published: 31-Dec-2011        Price: US 2000 Onwards        Pages: 0
    GlobalData's pharmaceuticals report, "Abraxane (Breast Cancer) - Analysis and Forecasts to 2020" provides Abraxane sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2005-2017). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalData's proprietary databa......
  • Trastuzumab-DM1 (Breast Cancer) - Analysis and Forecasts to 2020
    Published: 01-Feb-2012        Price: US 2000 Onwards        Pages: 0
    GlobalData's pharmaceuticals report, "Trastuzumab-DM1 (Breast Cancer) - Analysis and Forecasts to 2020" provides Trastuzumab-DM1 sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2016-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalData's prop......
  • Global Cancer Drug Market 2010-2014
    Published: 01-Feb-2012        Price: US 1500 Onwards        Pages: 30
    Increase in the prevalence of cancer worldwide is contributing majorly to the growth of this market. The Global Cancer Drug market in the Americas, and the EMEA and APAC region has been witnessing increasing use of a combination of therapies for cancer treatment. However, presence of alternative cancer treatments such as radiation therapy and surgery could pose a challenge to the growth of this market. ......
  • Targeted Cancer Drugs The Launch Landscape to 2018
    Published: 03-Feb-2012        Price: US 2265 Onwards        Pages: 306
    As the cancer therapy market evolves, interest is growing in novel approaches which may supersede the current portfolio. In the short term, the market will be dominated by established therapeutic approaches, but the question is – “What next?” A sign of things to come? The end of 2011 saw the US approval of two new molecularly-targeted cancer drugs, alongside companion diagnostic tests that identify the patients most likely to benefit from treatment. Pfizer's Xalkori (crizoti......
  • Anti-cancer Drugs Market in APAC 2011-2015
    Published: 04-Apr-2012        Price: US 1500 Onwards        Pages: 37
    TechNavio's analysts forecast the Anti-cancer Drugs market in the APAC region to grow at a CAGR of 23.7 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increase in the number of cancer patients. The Anti-cancer Drugs market in the APAC region has also been witnessing the trend of an increasing number of awareness campaigns. However, the presence of alternative cancer treatments such as radiation therapy and surgery could pose a challenge to the......
  • Anti-cancer Drugs Market in Japan 2011-2015
    Published: 05-Apr-2012        Price: US 1500 Onwards        Pages: 35
    TechNavio's analysts forecast the Anti-cancer Drugs market in Japan to grow at a CAGR of 11.1 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increase in the number of cancer patients in the country. The Anti-cancer Drugs market in Japan has also been witnessing the trend of using a combination of cancer therapies for treatment. However, stringent government regulations in Japan could pose a challenge to the growth of this market. ......
  • Global Breast Cancer Drugs Market 2011-2015
    Published: 19-Jul-2012        Price: US 1500 Onwards        Pages: 36
    TechNavio's analysts forecast the Global Breast Cancer Drugs market to grow at a CAGR of 1.7 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increasing prevalence of breast cancer worldwide. The Global Breast Cancer Drugs market has also been witnessing the trend of the emergence of combination therapies to treat breast cancer effectively. However, the availability of alternative treatment methods could pose a challenge to the growth of this ma......
  • Global Ovarian Cancer Drugs Market 2011-2015
    Published: 27-Aug-2012        Price: US 1500 Onwards        Pages: 36
    TechNavio's analysts forecast the Global Ovarian Cancer Drugs market to grow at a CAGR of 13.1 percent over the period 2011-2015. One of the key factors contributing to this market growth is the increasing prevalence of ovarian cancer. The Global Ovarian Cancer Drugs market has also been witnessing the trend of the use of combination therapies for the treatment of ovarian cancer. However, patent expiration of key drugs could pose a challenge to the growth of this market. TechNavio's report, t......
  • PharmaPoint: Prostate Cancer - Global Drug Forecast and Market Analysis to 2022
    Published: 30-Nov-2012        Price: US 9995 Onwards        Pages: 288
    GlobalData's report "PharmaPoint: Prostate Cancer Global Drug Forecast and Market Analysis to 2022", provides comprehensive information on prostate cancer therapeutics, highlighting the treatment guidelines and identifies and analyses the key trends shaping and driving the market. The report analyses the treatment usage patterns and provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Valuable insi......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs